Targets › BHMT
1 program from 1 company in 1 trial: 1 Phase 1; Genitourinary; next expected readout Oct 2028.
Involved in the regulation of homocysteine metabolism. Converts betaine and homocysteine to dimethylglycine and methionine, respectively. (UniProt, Q93088)
Open in Phaseline: the race on BHMT, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| United Therapeutics | 10 GE Xenokidney Porcine-derived kidney with intentional genomic alterations (knockout of GGTA1, CMAH, BHMT | GGTA1, CMAH, BHMT, PERV | Phase 1 | ESRD (End-Stage Renal Disease) | Oct 2028 |
ESRD (End-Stage Renal Disease) (1)
protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.